Table 5

Separating the effects of fat mass and fat free mass on prostate cancer

Gleason 6 PC

Gleason 7 PC

Gleason 8-10 PC

OR

95% CI

OR

95% CI

OR

95% CI


FM*

kg

0.987

0.974, 1.001

0.999

0.983, 1.015

1.005

0.983, 1.027

FFM

kg

1.015

0.997, 1.033

1.030

1.008, 1.052

1.044

1.014, 1.074

OR

95% CI

OR

95% CI

OR

95% CI


FM**

Q1

1.0

reference

1.0

reference

1.0

reference

Q2

0.99

0.70, 1.40

1.13

0.73, 1.74

0.79

0.40, 1.56

Q3

0.86

0.60, 1.24

1.19

0.75, 1.89

1.48

0.76, 2.88

Q4

0.75

0.50, 1.11

1.24

0.76, 2.01

0.97

0.47, 1.98

FFM

Q1

1.0

reference

1.0

reference

1.0

reference

Q2

1.03

0.72, 1.46

0.96

0.63, 1.46

1.02

0.52, 1.97

Q3

1.54

1.07, 2.21

1.07

0.68, 1.69

2.18

1.15, 4.27

Q4

1.32

0.88, 2.00

1.53

0.94, 2.50

2.62

1.26, 5.45


Table 5 includes analyses that describe the association between FFM or FM on PC after controlling for either FM or FFM. Analyses evaluate FM and FFM as either continuous variables or at quartiles

* PC = FM (continuous), FFM (continuous), age, prostate volume, PSA, race, family history, and current treatment for diabetes, CVD, BPH, and hyperlipidemia

** PC = FM (Quartiles), FFM (Quartiles), age, prostate volume, PSA, race, family history, and current treatment for diabetes, CVD, BPH, and hyperlipidemia

Fowke et al. BMC Cancer 2012 12:23   doi:10.1186/1471-2407-12-23

Open Data